Aptinyx (NASDAQ:APTX – Get Rating) released its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter in the prior year, the firm posted ($0.22) EPS.
NASDAQ APTX traded up $0.10 on Friday, hitting $0.70. 136,370 shares of the stock were exchanged, compared to its average volume of 312,910. The company has a debt-to-equity ratio of 0.15, a quick ratio of 20.18 and a current ratio of 20.18. The stock has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $2.43. The firm has a market capitalization of $47.40 million, a P/E ratio of -0.59 and a beta of 1.46. Aptinyx has a 52-week low of $0.57 and a 52-week high of $4.73.
Several equities research analysts recently weighed in on APTX shares. SVB Leerink reduced their price target on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Truist Financial reduced their price target on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, April 8th. Zacks Investment Research cut shares of Aptinyx from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. BMO Capital Markets reduced their price target on shares of Aptinyx from $12.00 to $6.00 in a research report on Friday, April 8th. Finally, HC Wainwright reduced their price target on shares of Aptinyx from $8.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, April 14th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $3.88.
Aptinyx Company Profile (Get Rating)
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.